Since such fibrosis is fundamental to the impairment of cardiac distensibility and glomerular function that characterizes obesity-related HFpEF, SGLT2 inhibitors can contribute to reduced perivisceral, perivascular, and pericardial adipose tissue deposition and inflammation. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.